MDM2 has been an attractive anti-cancer drug target, especially in tumours where p53 is wild-type with abnormal expression of MDM2.13, 14 The N-terminal binding interface between MDM2 and p53 was proven to be a promising drug target and the crystal structure for the N-terminal MDM2-p53 complex provided a starting point for structure-guided design of small molecules followed by successful co-crystallization attempts.15 The gene discussed is MDM2; the disease is neoplasm.